Ivermectin and mebendazole, 84% benefit in cancer (opens in new tab)

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response \+ Partial Response \+ Stable Disease / Total Patients \(CBR\) was 84\.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year\. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies\. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity\. This paper evaluates real-world patient-reported o...